MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) recorded quarterly Depreciation & Amortization (CF) of $800000.0 in Q1 2026, up 6.52% quarter-over-quarter from $751000.0 in Q4 2025, and up 100.0% on a YoY basis from $400000.0 in Q1 2025.
MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 100.0% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $3.0 million (up 107.0% YoY), while the FY2025 annual figure was $2.6 million, up 88.88% from the prior year.
- Depreciation & Amortization (CF) was $800000.0 for Q1 2026 at MoonLake Immunotherapeutics, up from $751000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $800000.0 in Q1 2026 to a low of $2488.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $283912.7 across 5 years, with a median of $328000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) sank 33.84% in 2022, then surged 11605.69% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $3289.0 in 2022, then changed by 0.0% to $3289.0 in 2023, then soared by 11605.69% to $385000.0 in 2024, then soared by 95.06% to $751000.0 in 2025, then advanced by 6.52% to $800000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $800000.0 (Q1 2026), $751000.0 (Q4 2025), and $745000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 751,000.00 |
| Dec 31, 2025 | 751,000.00 |
| Sep 30, 2025 | 745,000.00 |
| Sep 30, 2025 | 745,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 330,000.00 |
| Sep 30, 2024 | 330,000.00 |
| Jun 30, 2024 | 342,000.00 |
| Jun 30, 2024 | 342,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Dec 31, 2023 | 3,289.00 |
| Dec 31, 2023 | 3,289.00 |